目的 :寻找有效的多药耐药联合逆转剂。方法 :用逆转录 -聚合酶链反应 (RT -PCR) ,Westernblot和MTT法研究川芎嗪逆转耐药细胞系HL - 6 0 /VCR的作用 ,对多种化疗药物耐药的白血病用川芎嗪与环孢菌素A(CsA)加化疗药物联合用于治疗 2 1例复发难治性白血病。结果 :单用川芎嗪在体外能不同程度地增强HL- 6 0 /VCR细胞对多种化疗药物的敏感性 ,降低p170蛋白的表达。川芎嗪联合环胞素A有较好逆转复发难治性白血病多药耐药的作用 ,治疗组完全缓解率 44 4% ,部分缓解 33 3%。结论 :川芎嗪联合环胞素A可能成为安全有效的逆转药物 ,在治疗复发难治性白血病中有较大的临床意义和推广价值。 Objective: To find an effective multidrug resistance combination reversal agent. METHODS: Reverse transcriptase-polymerase chain reaction (RT-PCR), Western blot, and MTT assays were used to study the effect of ligustrazine on the reversal of HL-60/VCR in drug-resistant cell lines, and the use of tetramethylpyrazine for chemotherapy-resistant leukemias. Cyclosporin A (CsA) plus chemotherapeutic drugs were used to treat 21 cases of relapsed and refractory leukemia. RESULTS: Ligustrazine alone could enhance the sensitivity of HL-60/VCR cells to various chemotherapeutic drugs in vitro and reduce the expression of p170 protein. Ligustrazine combined with cyclosporine A has a good effect on reversing multidrug resistance of relapsed and refractory leukemia. The complete remission rate in the treatment group was 44%, and partial remission was 33%. Conclusion: Tetramethylpyrazine combined with cyclosporin A may be a safe and effective reversal drug. It has great clinical significance and popularization value in the treatment of relapsed and refractory leukemia.